Back to Journals » Virus Adaptation and Treatment » Volume 2

Antibody targeting of TSG101 on influenza-infected cells

Authors Bonavia A, Diaz LS, Santos D, Cassella J, Fesseha Z, Bamba D, Sui B, Li W, Duan R, Chen L, Donis RO, Goldblatt M, Kinch M

Published 9 November 2010 Volume 2010:2 Pages 147—157


Review by Single-blind

Peer reviewer comments 3

Aurelio Bonavia1*, Leyla S Diaz1*, David Santos1, Josephine Cassella1, Zena Fesseha1, Douty Bamba1, Baoquan Sui1, Wu-Bo Li1, Roxanne Duan1, Li-Mei Chen2, Ruben O Donis2, Michael Goldblatt1, Michael S Kinch1
1Functional Genetics, Inc, Gaithersburg, MD, USA; 2Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA; *These authors contributed equally to this work.

Abstract: Influenza remains a significant cause of morbidity and mortality worldwide. Although vaccination programs and conventional antiviral therapies can reduce disease burden, increasing resistance to conventional therapies renders much of the population susceptible to infection. The present study focuses on an important host protein target, tumor susceptibility gene 101 (TSG101), which is functionally exploited (hijacked) by certain enveloped viruses to facilitate viral budding and release. We find that influenza viruses depend on TSG101 for progeny virion morphogenesis in infected host cells. Antibody-binding studies revealed that TSG101 is exposed at the surface of influenza-infected cells but remains intracellular in uninfected cells. Using recombinant TSG101 and influenza M1 protein, we demonstrated a direct interaction between these proteins involving the ubiquitin E2 variant domain of TSG101. These findings identify an interaction between TSG101 and M1 protein in infected cells. Furthermore, a monoclonal antibody directed against TSG101 reduced virus yields in cell-based assessment of influenza virus infection, underscoring the potential of the TSG101-M1 interaction as a possible antiviral therapeutic target. The display of TSG101 at the surface of infected cells, combined with evidence that TSG101 antibodies reduce virus yields, suggest that TSG101 plays an essential role in the budding process of influenza virus. Our findings may also suggest potential opportunities for influenza treatment and prevention by using monoclonal antibody therapeutics to interfere with virus replication.

Keywords: influenza, TSG101, infected cells, vaccine

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Development of FGI-106 as a broad-spectrum therapeutic with activity against members of the family Bunyaviridae

Darci R Smith, Monica Ogg, Aura Garrison, et al

Virus Adaptation and Treatment 2010, 2:9-20

Published Date: 26 February 2010

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012


Chen ZQ, Liu Y, Zhao JH, Wang L, Feng NP

International Journal of Nanomedicine 2012, 7:1709-1710

Published Date: 30 March 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010